Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abraxis BioScience Inc.

Division of Bristol-Myers Squibb Co.
www.abraxisbio.com

Latest From Abraxis BioScience Inc.

India's SPARC Keeps Paclitaxel Ambition Burning For Now

A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.

Research & Development Clinical Trials

Keeping Track: US Approvals For Xpovio And Xembify Highlight Short Holiday Week

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review

French Court Wants EU Clarity On SPCs For New Uses

A second referral has been made to the Court of Justice of the EU on the tricky question of whether a new formulation or use of an authorized medicine can be granted its own supplementary protection certificate.

Intellectual Property Europe

Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer

Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

ImmunoOncology Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register